Empagliflozin patent expiration in India leads to affordable treatment for diabetes, heart failure, and kidney disease.

Empagliflozin, which in addition to treating type-2 diabetes, also aids weight loss, and reduces cardiovascular and kidney ...

Homegrown pharmaceutical companies launching significantly cheaper generic versions of empagliflozin—a widely prescribed ...

Mankind Pharma and other domestic companies have launched generic versions of the popular diabetes drug Empagliflozin at ...

Discover preclinical studies that indicate that empagliflozin reduces liver fat, improves liver function markers, and ...

Several domestic drug makers, including Mankind Pharma, have launched the diabetes drug Empagliflozin at significantly ...

Glenmark and Alkem Labs launched the generic version as well as its Fixed Dose Combination (FDCs) of Empagliflozin in India.

Prices of key anti-diabetic drug empagliflozin crashed by as much as 90 per cent to ₹5.5 per tablet as several pharma ...

Empagliflozin is effective in improving the clinical outcomes in patients with acute heart failure and low BP without further ...

Glenmark Pharmaceuticals on Wednesday said it has launched a medication for glycemic control and weight-loss for diabetes ...

Mankind Pharma has launched a generic version of Empagliflozin in India under the brands Empaglyde, Empagreat, and Dynaduo. The launch breaks cost barriers, offering the medication at competitive ...

The biggest advantage of the drug going off patent is that the prices will plummet. The patented medicine, sold as Jardiance, ...